The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn’s Disease or Ulcerative Colitis
Background: The anti-TNF drugs adalimumab (ADA) and infliximab (IFX) are effective treatments for inflammatory bowel disease (IBD). However, 40% of patients lose response, often due to the development of antibodies-to-ADA (ATA) and antibodies-to-IFX (ATI). While low ATA/ATI titres (<200 ng/mL) a...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2022-03-01
|
| Series: | European Medical Journal |
| Online Access: | https://www.emjreviews.com/gastroenterology/article/the-impact-of-intermediate-antidrug-antibodies-to-infliximab-and-adalimumab-on-clinical-outcomes-in-patients-with-crohns-disease-or-ulcerative-colitis-j190121/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|